Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response

British Journal of Ophthalmology

Volumn 98, Issue 2, 2014, Pages 188-194

  Hatz, Katja ^a,b   Prünte, Christian ^a,b  

^a Vista Klinik   (Switzerland)

^b Kantonsspital Liestal ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT DURATION;

IMAGING; MACULA; NEOVASCULARISATION; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; CHOROIDAL NEOVASCULARIZATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SWITZERLAND; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84892617210     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303444     Document Type: Article

References (31)

1. Nguyen DH, Luo J, Zhang K, et al. Current therapeutic approaches in neovascular age-related macular degeneration. Discov Med 2013; 15: 343-8.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44. (Pubitemid 44511558)
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31. (Pubitemid 44511557)
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83.
6. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-71.
7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
8. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147: 831-7.
9. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009; 148: 70-8.
10. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010; 150: 666-73.
11. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416-34. (Pubitemid 32971350)
12. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004; 49: 25-37. (Pubitemid 38056622)
13. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010; 29: 19-29.
14. Costa RA, Navajas EV, Farah ME, et al. Polypoidal choroidal vasculopathy: angiographic characterization of the network vascular elements and a new treatment paradigm. Prog Retin Eye Res 2005; 24: 560-86. (Pubitemid 40943662)
15. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010; 55: 501-15.
16. Khan S, Engelbert M, Imamura Y, et al. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings. Retina 2012; 32: 1057-68.
17. Lima LH, Schubert C, Ferrara DC, et al. Three major loci involved in age-related macular degeneration are also associated with polypoidal choroidal vasculopathy. Ophthalmology 2010; 117: 1567-70.
18. Freund KB, Ho IV, Barbazetto IA, et al. Type neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008; 28: 201-11. (Pubitemid 351643149)
19. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type neovascularization. Retina 2008; 28: 375-84. (Pubitemid 351354939)
20. Koh AH, Chen LJ, Chen SJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33: 686-716.
21. Visudyne: EPAR - Product Information - European Medicines Agency. Annex1. Summary of product characteristics. http: //www.ema.europa.eu/ema/ (last updated
22. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111: 1576-84. (Pubitemid 39030815)
23. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453-64.
24. de Crecchio G, Chan RV, Manzi G, et al. Polypoidal choroidal vasculopathy: recent advances in therapy. Curr Drug Targets 2011; 12: 206-11.
25. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 2000; 238: 752-9.
26. Reche-Frutos J, Calvo-Gonzalez C, Perez-Trigo S, et al. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome. Eur J Ophthalmol 2011; 21: 783-8.
27. Konstantinidis L, Mameletzi E, Mantel I, et al. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009; 247: 1165-71.
28. Parravano M, Pilotto E, Musicco I, et al. Reproducibility of fluorescein and indocyanine green angiographic assessment for RAP diagnosis: a multicenter study. Eur J Ophthalmol 2012; 22: 598-606.
29. Massacesi AL, Sacchi L, Bergamini F, et al. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 89-92. (Pubitemid 350162687)
30. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2000; 107: 742-53.
31. Kuerzinger GR, Lang GK, Lang GE. Retinal angiomatous proliferation in age-related macular degeneration. Klin Monbl Augenheilkd 2006; 223: 691-5. (Pubitemid 44681091)